Unicycive Therapeutics Inc

NASDAQ:UNCY   12:58:32 AM EDT
0.67
-0.06 (-7.83%)
Earnings Announcements

Unicycive Announces Third Quarter Financial Results

Published: 11/14/2022 13:29 GMT
Unicycive Therapeutics Inc (UNCY) - Unicycive Announces Third Quarter Financial Results and Provides Business Update.
On Track to File New Drug Application for Renazorb in 2023.
Qtrly Loss per Share $0.37.
As of September 30, 2022, Cash and Cash Equivalents Totaled $7.0 Million.
Q3 Earnings per Share View $-0.28 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.